// App-Quantinova.ai

TCT CONNECT-262 : Percutaneous Coronary Intervention of Long Coronary Lesions With the Bioabsorbable Polymer-Coated, Everolimus-Eluting Synergy 48-mm Stent: Primary Outcomes of the EVOLVE 48 Study

Researchers

Presenter

  • Dimitrios Karmpaliotis

Principal Investigators

  • Robert Stoler

  • Simon Walsh

  • Seif El-Jack

  • Srini Potluri

  • Jeffrey Moses

  • Keith Oldroyd

  • Adrian Banning

  • Mark Webster

  • Azfar Zaman

  • Willis Wu

  • Mudassar Ahmed

  • Paul Underwood

  • Dominic Allocco

Medical Centers

  • NewYork–Presbyterian/Columbia University Irving Medical Center, New York, New York, USA

  • Baylor Scott & White Heart and Vascular Hospital, Dallas, Texas, USA

  • Royal Victoria Hospital, Belfast, United Kingdom

  • Boston Scientific, Maple Grove, MN

  • Boston Scientific, Phoenix, Arizona, USA

  • M Health Fairview St Joseph’s Hospital, St. Paul, Minnesota

  • Golden Jubilee National Hospital, Clydebank, United Kingdom

  • Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom

  • The Heart Hospital Baylor Plano, Plano, TX

  • John Radcliffe Hospital, Oxford, United Kingdom.

  • REX Hospital, Raleigh, North Carolina

  • Auckland City Hospital, Auckland, New Zealand

  • North Shore Hosp, Auckland, New Zealand

Locations

  • United States

  • United Kingdom

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • Promus Element

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved